Overall Survival Analysis of the Use of Elotuzumab in ELOQUENT-3 Trial
| Errataetall: |
CommentOn: J Clin Oncol. 2023 Jan 20;41(3):568-578. - PMID 35960908 |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:41 |
|---|---|
| Enthalten in: |
Journal of clinical oncology : official journal of the American Society of Clinical Oncology - 41(2023), 9 vom: 20. März, Seite 1788 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Al Hadidi, Samer [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
1351PE5UGS |
|---|
| Anmerkungen: |
Date Completed 20.03.2023 Date Revised 15.02.2024 published: Print-Electronic CommentOn: J Clin Oncol. 2023 Jan 20;41(3):568-578. - PMID 35960908 Citation Status MEDLINE |
|---|
| doi: |
10.1200/JCO.22.02098 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM351377271 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM351377271 | ||
| 003 | DE-627 | ||
| 005 | 20240215231838.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1200/JCO.22.02098 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1294.xml |
| 035 | |a (DE-627)NLM351377271 | ||
| 035 | |a (NLM)36626704 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Al Hadidi, Samer |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Overall Survival Analysis of the Use of Elotuzumab in ELOQUENT-3 Trial |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 20.03.2023 | ||
| 500 | |a Date Revised 15.02.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a CommentOn: J Clin Oncol. 2023 Jan 20;41(3):568-578. - PMID 35960908 | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Letter | |
| 650 | 4 | |a Comment | |
| 650 | 7 | |a elotuzumab |2 NLM | |
| 650 | 7 | |a 1351PE5UGS |2 NLM | |
| 650 | 7 | |a Antibodies, Monoclonal, Humanized |2 NLM | |
| 650 | 7 | |a Dexamethasone |2 NLM | |
| 650 | 7 | |a 7S5I7G3JQL |2 NLM | |
| 700 | 1 | |a van Rhee, Frits |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of clinical oncology : official journal of the American Society of Clinical Oncology |d 1986 |g 41(2023), 9 vom: 20. März, Seite 1788 |w (DE-627)NLM012608777 |x 1527-7755 |7 nnns |
| 773 | 1 | 8 | |g volume:41 |g year:2023 |g number:9 |g day:20 |g month:03 |g pages:1788 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1200/JCO.22.02098 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 41 |j 2023 |e 9 |b 20 |c 03 |h 1788 | ||